Celldex is building a commercial team to launch barzolvolimab, the most advanced anti‑KIT therapy in pivotal development with Phase 3 trials in CSU and other indications. We seek curious, driven builders who connect daily work to enterprise impact, prioritise what matters, and deliver on commitments with urgency and ownership.
Join a high‑growth, entrepreneurial environment where collaboration with R&D and other functions shapes strategy, governance, and commercial success through clear value
#J-18808-Ljbffr